MPM Capital is a healthcare investment firm founding and investing in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM invests in breakthrough therapeutics, with a focus on oncology. With its experienced and dedicated team of investment professionals, executive partners, entrepreneurs and scientific advisory board members, MPM is powering novel medical breakthroughs that transform patients’ lives.
Making an Impact Through Innovation
MPM continuously seeks new ways to invest in order to drive breakthroughs and cures, and two of its strategies feature innovative impact components:
- The first is a crossover strategy (both public and private equities) that donates a portion of profits and royalties to cancer care and research. Through its partnership with the American Association of Cancer Research, the first gift of $1.2 million was made in 2018 to the joint AACR-MPM Transformative Cancer Research Grants Program. An equal amount was also donated to the UBS Optimus Foundation to support emerging market access to cancer care.
- The second features a philanthropy-investment opportunity involving Dana-Farber Cancer Institute (DFCI) to advance cancer research. This unique philanthropy-investment opportunity gives MPM early insight into DFCI projects with commercial potential and provides DFCI with potential new philanthropic resources.